Imidazopyridine Compounds Target Chaperones to Degrade ERα
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for breast, prostate, and endometrial cancers that target steroid hormone receptors, such as estrogen and androgen receptors, face challenges due to resistance development, particularly through mutations in the ligand binding domain, necessitating the development of antagonists that function indirectly through cofactors to enhance receptor activity.
Innovation Solution
The use of imidazopyridine compounds, specifically represented by X15695, which act as selective estrogen and androgen receptor antagonists by targeting molecular chaperones and cochaperones, disrupting BAG1/mortalin interactions, and reactivating p53, thereby inhibiting cancer cell proliferation without relying on the ligand binding domain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies target the ligand binding domain of steroid hormone receptors, then initial therapeutic efficacy is achieved, but resistance develops through mutations in the LBD
Solution Approach 1:
The patent uses molecular chaperones and cochaperones as intermediary targets. Instead of directly targeting the ligand binding domain of steroid hormone receptors, the invention targets proteins that regulate receptor activity and stability. This indirect approach allows the therapy to affect receptor function without being subject to mutations in the receptor's LBD, thereby resolving the contradiction between initial efficacy and resistance development
Solution Approach 2:
The patent changes the target parameter from the receptor's ligand binding domain to upstream regulatory proteins (molecular chaperones and cochaperones). By targeting different parameters in the signaling pathway, the therapy can achieve sustained efficacy even when the original target becomes resistant through mutation
2Reliability
If ER antagonists such as tamoxifen are used for endometrial cancer, then some therapeutic effect is achieved, but inconsistent results occur with limited efficacy and potential increased cancer risk
Solution Approach 1:
The patent employs molecular chaperones and cochaperones as intermediary targets to regulate ERα activity indirectly. This approach provides more consistent and reliable therapeutic effects compared to direct ER antagonism, while avoiding the harmful side effects associated with classical ER antagonists in endometrial cancer treatment
Solution Approach 2:
Instead of using antagonists that block ER activity directly (which cause harmful effects), the patent inverts the approach by using compounds that modulate ER activity through chaperone regulation, achieving therapeutic benefit without the harmful side effects of direct antagonism
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
The present invention relates to specific imidazopyridine compounds for use in the treatment of breast cancers, prostate cancers, and endometrial cancers.